Target (CBDY) Convertible Debt (2016 - 2019)
Target (CBDY) reported Convertible Debt of $168300.0 for Q4 2019, up 20.21% quarter-over-quarter from $140000.0 in Q1 2018.
Target (CBDY) Convertible Debt (2016 - 2019) Analysis & Trends
Target (CBDY) has 3 years of Convertible Debt data on file, last reported at $168300.0 in Q4 2019.
- Convertible Debt for Q4 2019 came in at $168300.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $168300.0 (changed N/A YoY), and the FY2019 annual result was $168300.0, changed N/A from the prior year.
- Convertible Debt grew to $168300.0 in Q4 2019 per CBDY's latest filing, from $140000.0 in the prior quarter.
- Over five years, Convertible Debt peaked at $168300.0 in Q4 2019 and troughed at $75000.0 in Q3 2016.
- A 3-year average of $136660.0 and a median of $150000.0 in 2016 frame the typical range for Convertible Debt.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Target | - | - | 191,787.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 168,300.00 |
| Mar 31, 2018 | 140,000.00 |
| Sep 30, 2016 | 75,000.00 |
| Jun 30, 2016 | 150,000.00 |
| Mar 31, 2016 | 150,000.00 |